Conference Presentation, Interview, Fireside Chat
Daniel Nadler on Building an AI-Powered Search Engine for Medicine
- Open Evidence's mission is to function as the "MRI of medical knowledge," enabling physicians to access the full body of medical data at the point of care to reduce medical errors and improve treatment decisions.
- The company was founded by Dr. Daniel Nadler following a sabbatical and a realization during the COVID-19 pandemic that the volume of medical literature had become unmanageable for individual practitioners.
- Nadler compared the information overload in medicine to the financial industry, noting that while analysts cover a manageable universe of 100 companies, oncologists are expected to master the details of 100 cancer drugs, including side effects and drug interactions, which is an impossible standard.
- Second opinion studies indicate that 88% of initial medical opinions are changed by a second opinion, with 20% completely overturned, highlighting significant unwanted variance based on the specific physician consulted.
- Open Evidence aims to eliminate this variance by aligning physicians to the same standard of care, ensuring that "nobody is rolling the dice" on patient treatment.
- The company targets reducing the "bench-to-bedside" transmission lag, shifting the timeline from an average 17-year delay to roughly 17 hours, ensuring physicians immediately understand new FDA-approved treatments.
- The platform currently powers 1.5 million verified queries in the United States, serving a usage footprint that will impact 300 million American patients treated by a physician using the tool this year.
- Usage patterns skew heavily toward complex specialties such as oncology, Alzheimer's, and Parkinson's, while family physicians remain underrepresented due to the lower complexity of their routine cases.
- Unlike generalized large language models that rely on public data and often hallucinate or provide abstract-only summaries, Open Evidence operates as an official AI partner for major medical publishers.
- The company secured formal partnerships with the New England Journal of Medicine and the National Comprehensive Cancer Network (NCCN), mirroring the "iTunes model" of licensing where publishers are economically involved and receive compensation.
- Access to full-text data, including tables and charts (e.g., progression-free survival decay curves), allows Open Evidence to answer granular clinical questions that generic LLMs cannot, such as demographic specifics in trial arms.
- Google is identified as the company's largest investor, validating the platform's search-engine-first architecture within the medical domain.
- Open Evidence plans to address the clinical trial bottleneck by matching patients with relevant trials, aiming to increase the discovery rate of eligible trials for cancer patients, currently standing at fewer than 10%.
- Approximately one in three clinical trials are discontinued due to a failure to recruit sufficient patients, a gap the company seeks to close by making trial eligibility data visible to both doctors and patients.
- Nadler intends to remain in the medical technology sector for the rest of his career, viewing the integration of AI into healthcare as a form of philanthropy rather than a business to be sold and exited.
- The long-term goal is to knock medical error out of the top 10 causes of death in the United States by standardizing knowledge access across the healthcare system.